Comparative Study Between Three Different Techniques in Drainage of SRF During PPV in RRD
Launched by AIN SHAMS UNIVERSITY · Mar 20, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying three different methods for draining fluid from under the retina in patients who have a specific type of eye condition called rhegmatogenous retinal detachment (RRD) that affects the macula, the part of the eye responsible for sharp vision. The goal is to see which technique is most effective at reducing the fluid and preventing complications during and after surgery. The three methods being compared include using the original tear in the retina, making a new opening in the retina for drainage, and using a specific type of fluid to help with the drainage process.
To be eligible for this trial, participants must be over 18 years old and have RRD involving the macula, with a recent duration of detachment (less than one month). They should also have certain conditions related to the detachment, like mild proliferative vitreoretinopathy (PVR). However, individuals with other types of retinal detachment, severe PVR, or specific eye conditions will not be included. If you participate, you will receive one of the three treatment techniques and will be monitored for how well the fluid is drained and any possible complications that may arise during your recovery. This study is important because it aims to find the best way to treat this condition and improve outcomes for patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Age: above 18 years old
- • Patients with rhegmatogenous retinal detachment (RRD) where the detachment is involving the macula.
- • Patients with proliferative vitreoretinopathy (PVR) no more than PVR -B.
- • Patients with peripheral break.
- • Duration of detachment: within one month.
- Exclusion Criteria:
- • • Patients with macula on RRD.
- • Patients with tractional retinal detachment.
- • Patients with giant retinal tear.
- • Patients with proliferative vitreoretinopathy (PVR) more than PVR -B.
- • More than one month duration of detachment.
- • Patients with posterior staphyloma.
- • Patients with recurrent retinal detachment.
- • Patients with full thickness macular hole.
About Ain Shams University
Ain Shams University, established in Cairo, Egypt, is a prestigious higher education institution renowned for its commitment to academic excellence and research innovation. As a clinical trial sponsor, the university leverages its extensive resources and expertise in various medical and scientific disciplines to advance healthcare through rigorous research initiatives. With a focus on ethical practices and adherence to regulatory standards, Ain Shams University aims to contribute to the development of new therapies and improve patient outcomes, fostering collaboration among researchers, healthcare professionals, and industry partners in the pursuit of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Dina T Mohamed, master's
Principal Investigator
AinShams University
Tamer F Elewa, MD
Study Chair
AinShams University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported